Pharmexa courts merger opportunities  

Danish therapeutic vaccine company Pharmexa eyes potential mergers with pharma or biotech companies

According to a report in Jyllands-Posten, Danish biotech company Pharmexa has made known its interest in potential mergers with other pharmaceutical or biotech companies. The company, which already counts H. Lundbeck and Schering-Plough amongst its collaboration partners, expects that consolidation will soon occur among biotech SMEs involved in immune therapy.


Pharmexa is a leading company in the field of therapeutic vaccines (pharmaccines) for the treatment of serious chronic diseases, and currently focuses its resources on a number of cancer forms and chronic inflammatory diseases. Pharmexa's product pipeline targets breast cancer, rheumatoid arthritis, osteoporosis, asthma, allergy and certain CNS diseases.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×